Neurology Central

Aimovig® receives EMA license for the prevention of migraine

Novartis (Frimley, UK) has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved in the European Union, Switzerland, the USA and Australia.

The latest information on migraine reveals that over 610,000 individuals in the UK are estimated to experience chronic migraines (15 or more headache days per month, of which eight involve migraine symptoms), with the 2010 Equality Act classifying migraine as a disability should the condition have a long-term, substantial impact on day to day or work-related activities.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.